Naropa University Launches its 43rd Annual Summer Writing Program
↧
↧
Constellation Alpha Capital Corp. Announces Pricing of $125 Million Initial Public Offering
↧
Torrance Memorial Experiences Phishing Incident
TORRANCE, Calif., June 19, 2017 /PRNewswire/ -- On April 20, 2017, Torrance Memorial Medical Center (Torrance Memorial) discovered an email security incident that had taken place on April 18 and 19, 2017. The incident allowed access to two email accounts which contained work-related...
↧
InfuSystem's Board Of Directors Rejects 22NW Fund's Unsolicited Proposal As Inadequate
↧
Thousands Joined Archbishop Gomez For Special Mass In Solidarity With All Immigrants
↧
↧
New ARMY Logistics Systems Training Services Offered for GCSS-Army
↧
CIOMA Ventures Across the State to Educate Members About the Fuel Industry and Convenience Store Issues
↧
The Arkansas River is No. 1 for whitewater rafting tours in Colorado
↧
Registration Opens for 2017 Global Tourism Summit in Honolulu, Sept. 19-21
↧
↧
Miles se unieron al Arzobispo Gomez para una misa especial en solidaridad con todos los inmigrantes
↧
Новинка от Supermicro - X11 SuperBlade®, - повышает производительность I/O и оснащена коммутационной матрицей Intel® Omni-Path
↧
Novo SuperBlade® X11 da Supermicro incrementa o desempenho de I/O com a estrutura Omni-Path da Intel®
↧
Shareholder Class Action Filed Against Booz Allen Hamilton Holding Corp. - BAH
↧
↧
Shire plc: U.S. FDA Approves Mydayis[TM] (Mixed Salts of a Single-Entity Amphetamine Product) - A New Once-Daily Option for ADHD Symptom Control in Patients 13 Years and Older
LEXINGTON, Massachusetts, June 20, 2017 /PRNewswire/ --
Shire plc (LSE: SHP, NASDAQ: SHPG) announced today that the U.S. Food and Drug Administration (FDA) has approved MYDAYIS[TM] (mixed salts of a single-entity amphetamine product), a once-daily treatment comprised of three...
↧
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aaron's, Inc. -- AAN
↧
AJC Praises Diplomatic Efforts to Marginalize UN Human Rights Council Item on Israel
↧
Joint Reconstruction Devices Market is expected to reach USD 30.4 billion by 2025
↧
↧
Novo Nordisk receives positive 17-2 vote from FDA Advisory Committee that Victoza® provides substantial evidence of cardiovascular risk reduction in patients with type 2 diabetes
↧
Una medición exacta de los puntos focales gracias a la cámara RaySafe Pro-Slit
↧
Manulife's Investor Day 2017
↧
More Pages to Explore .....